Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AKTX Stock Summary
Top 10 Correlated ETFs
AKTX
In the News
Akari Therapeutics to Present at Biotech Showcase 2024
NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development of PASylated®-Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference taking place November 14-16 in Boston, MA. The poster will be presented on November 15, 2023 at 3:00 pm ET.
Akari Therapeutics to Present at Emerging Growth Conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.
Best Penny Stocks To Buy? 6 To Watch Before Next Week
Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.
Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down
There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.
Akari Therapeutics to Present at Biotech Showcase™ 2023
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari's two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program investigating long-acting PAS-nomacopan as a potential treatment for geographic atrophy.
Akari Therapeutics (AKTX) Stock: Why It 27.88%
The stock price of Akari Therapeutics (AKTX) fell by 27.88% in the most recent trading session. This is why.
Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting
NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American Thoracic Society (ATS) 2022 Annual Meeting reporting results from the CORONET and CASCADE studies in patients with COVID-19 pneumonia.
Akari Therapeutics to Present at BIO CEO & Investor Conference
NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer of Akari Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:30 p.m. ET, at the New York Marriott Marquis.
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present a Company overview at the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022.
AKTX Financial details
AKTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.26 | -0.97 | -0.56 | -0.41 | -0.11 | |
Operating cash flow per share | -1.43 | -0.55 | -0.54 | -0.44 | -0.34 | |
Free cash flow per share | -1.43 | -0.55 | -0.54 | -0.44 | -0.34 | |
Cash per share | 0.38 | 0.26 | 0.44 | 0.22 | 0.21 | |
Book value per share | 0.85 | 0.17 | 0.39 | 0.13 | 0.03 | |
Tangible book value per share | 0.84 | 0.17 | 0.39 | 0.13 | 0.03 | |
Share holders equity per share | 0.85 | 0.17 | 0.39 | 0.13 | 0.03 | |
Interest debt per share | -0.01 | 0 | 0 | 0 | -0.09 | |
Market cap | 496.34M | 786.05M | 1.17B | 1.29B | 586.89M | |
Enterprise value | 490.37M | 780.32M | 1.15B | 1.28B | 573.64M | |
P/E ratio | -24.88 | -36.12 | -66.42 | -73.13 | -84.17 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -22.02 | -64.13 | -68.95 | -68.32 | -27.29 | |
PFCF ratio | -22.02 | -64.13 | -68.95 | -68.32 | -27.29 | |
P/B Ratio | 37.11 | 204.91 | 94.45 | 231.81 | 327.73 | |
PTB ratio | 37.11 | 204.91 | 94.45 | 231.81 | 327.73 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -20.83 | -31.21 | -55.92 | -75.12 | -20.11 | |
EV to operating cash flow | -21.76 | -63.66 | -68.13 | -67.83 | -26.68 | |
EV to free cash flow | -21.76 | -63.66 | -68.13 | -67.83 | -26.68 | |
Earnings yield | -0.04 | -0.03 | -0.02 | -0.01 | -0.01 | |
Free cash flow yield | -0.05 | -0.02 | -0.01 | -0.01 | -0.04 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0.25 | 0.23 | 0.68 | 0.55 | 0.46 | |
Current ratio | 5.33 | 1.88 | 3.37 | 1.91 | 1.15 | |
Interest coverage | 243.8 | 0 | 0 | 0 | 4.32 | |
Income quality | 0.96 | 0.5 | 0.83 | 1.08 | 1.21 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.9 | 1.93 | 2.22 | 1.09 | 0.27 | |
ROIC | -1.27 | -5.7 | -1.25 | -3.13 | -5.06 | |
Return on tangible assets | -1.22 | -2.12 | -1 | -1.51 | -0.5 | |
Graham Net | 0.61 | 0.1 | 0.35 | 0.08 | 0.03 | |
Working capital | 13.32M | 4.82M | 12.35M | 5.53M | 1.77M | |
Tangible asset value | 13.34M | 3.81M | 12.35M | 5.53M | 1.77M | |
Net current asset value | 13.32M | 3.8M | 12.35M | 5.53M | 1.77M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 5.22M | 7.49M | 4.03M | 1.76M | 1.48M | |
Average payables | 1.78M | 1.41M | 2.3M | 2.58M | 1.37M | |
Average inventory | -1M | -1.52M | -778.41K | -260.94K | -1.24M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 23.34K | 138.51K | 158.22K | 93.19K | |
Days of inventory on hand | 0 | -19.67K | -21.39K | 0 | -244.69K | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.02 | 0 | 0 | 0 | |
Inventory turnover | 0 | -0.02 | -0.02 | 0 | 0 | |
ROE | -1.49 | -5.67 | -1.42 | -3.17 | -3.89 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-11-08 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.01 | -1.01 | -0.34 | -0.34 | 0 | |
Operating cash flow per share | -1.15 | -1.15 | -1.09 | -1.09 | 0 | |
Free cash flow per share | -1.15 | -1.15 | -1.09 | -1.09 | 0 | |
Cash per share | 3.88 | 3.88 | 1.63 | 1.63K | 0 | |
Book value per share | 0.52 | 0.52 | 0.63 | 633.16 | 0 | |
Tangible book value per share | 0.52 | 0.52 | 0.63 | 629.56 | 0 | |
Share holders equity per share | 0.52 | 0.52 | 0.63 | 633.16 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 32.14K | 32.14K | 15.99K | 14.94K | 0 | |
Enterprise value | 18.89K | 18.89K | 8.81K | -7.17M | 0 | |
P/E ratio | -2.33 | -2.33 | -2.67 | -2.49 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -8.16 | -8.16 | -3.34 | -3.12 | 0 | |
PFCF ratio | -8.16 | -8.16 | -3.34 | -3.12 | 0 | |
P/B Ratio | 17.95 | 17.95 | 5.75 | 0.01 | 0 | |
PTB ratio | 17.95 | 17.95 | 5.75 | 0.01 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -3.14 | -3.14 | -1.91 | 1.56K | 0 | |
EV to operating cash flow | -4.79 | -4.79 | -1.84 | 1.5K | 0 | |
EV to free cash flow | -4.79 | -4.79 | -1.84 | 1.5K | 0 | |
Earnings yield | -0.11 | -0.11 | -0.09 | -0.1 | 0 | |
Free cash flow yield | -0.12 | -0.12 | -0.3 | -0.32 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 2.2 | 2.2 | 1.56 | 1.56K | 0 | |
Current ratio | 1.15 | 1.15 | 1.53 | 1.53 | 0 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 1.14 | 1.14 | 3.19 | 3.19 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.45 | 3.45 | 2.21 | 69.73 | 0 | |
ROIC | -3.36 | -3.36 | -1.66 | 0 | 0 | |
Return on tangible assets | -0.25 | -0.25 | -0.19 | 0 | 0 | |
Graham Net | 0.35 | 0.35 | 0.44 | 443.7 | 0 | |
Working capital | 1.77K | 1.77K | 2.77K | 2.77M | 0 | |
Tangible asset value | 1.77K | 1.77K | 2.77K | 2.77M | 0 | |
Net current asset value | 1.77K | 1.77K | 2.77K | 2.77M | 0 | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 817.86K | 946.66 | 988.64 | 515.83K | 515.31K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.92 | -1.92 | -0.54 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AKTX Frequently Asked Questions
What is Akari Therapeutics, Plc stock symbol ?
Akari Therapeutics, Plc is a GB stock and trading under the symbol AKTX
Is Akari Therapeutics, Plc buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $12000. The lowest prediction is $12000 and the highest is $12000
What is AKTX stock prediction ?
What is Akari Therapeutics, Plc stock quote today ?
Akari Therapeutics, Plc stock price is $1.835 today.
Is Akari Therapeutics, Plc stock public?
Yes, Akari Therapeutics, Plc is a publicly traded company.